
  
    
      
        
        Hepatitis_NNP B_NNP is_VBZ a_DT serious_JJ global_JJ public_JJ health_NN problem_NN but_CC is_VBZ preventable_JJ with_IN safe_JJ and_CC
        effective_JJ vaccines_NNS that_WDT have_VBP been_VBN available_JJ since_IN 1982_CD ._. Despite_IN these_DT vaccines_NNS ,_, about_IN 2_CD
        billion_CD people_NNS have_VBP been_VBN infected_VBN with_IN hepatitis_NNP B_NNP virus_NN (_( HBV_NNP )_) ,_, and_CC more_JJR than_IN 350_CD million_CD
        have_VBP lifelong_JJ infections_NNS ._. These_DT chronically_RB infected_JJ people_NNS are_VBP at_IN high_JJ risk_NN of_IN death_NN from_IN
        cirrhosis_NNS of_IN the_DT liver_NN and_CC liver_NN cancer_NN ,_, which_WDT both_DT kill_NN about_RB 1_CD million_CD people_NNS each_DT
        year_NN ._.
        Suppression_NN of_IN viral_JJ replication_NN in_IN chronic_JJ carriers_NNS of_IN HBV_NNP is_VBZ an_DT effective_JJ approach_NN to_TO
        controlling_VBG disease_NN progression_NN ._. Current_JJ antiviral_JJ therapies_NNS include_VBP lamivudine_NN and_CC
        alpha-interferon_JJ ,_, but_CC long-term_JJ resolution_NN of_IN the_DT disease_NN is_VBZ disappointing_JJ because_IN of_IN low_JJ
        seroconversion_NN rates_NNS and_CC the_DT development_NN of_IN drug-resistant_JJ viral_JJ mutants_NNS ._.
        In_IN this_DT month_NN 's_POS 
        PLoS_NNP Medicine_NNP ,_, Lisa_NNP F_NNP ._. P_NN ._. Ng_NNP and_CC colleagues_NNS describe_VBP the_DT identification_NN
        of_IN a_DT host_NN factor_NN that_WDT has_VBZ a_DT significant_JJ effect_NN on_IN viral_JJ replication_NN efficiency_NN ._. The_DT team_NN
        began_VBD by_IN examining_VBG the_DT serum_NN viral_JJ load_NN of_IN a_DT group_NN of_IN carriers_NNS of_IN hepatitis_NNP B_NNP in_IN relation_NN
        to_TO the_DT HBV_NNP genome_NN carried_VBD ._. They_PRP found_VBD a_DT significant_JJ association_NN between_IN high_JJ serum_NN viral_JJ
        load_NN and_CC a_DT natural_JJ sequence_NN variant_NN within_IN the_DT HBV_NNP enhancer_NN II_NNP regulatory_JJ region_NN at_IN
        position_NN 1752_CD ._. Upon_IN testing_VBG all_DT four_CD possible_JJ 1752_CD variants_NNS ,_, the_DT 1752_CD A_DT variant_NN had_VBD the_DT
        highest_JJS transcriptional_NN activity_NN ._.
        Further_RB investigation_NN of_IN this_DT enhanced_JJ transcriptional_NN activity_NN revealed_VBD evidence_NN of_IN
        possible_JJ interaction_NN with_IN host_NN DNA_NNP binding_JJ proteins_NNS ._. The_DT team_NN found_VBD that_IN a_DT protein_NN present_JJ
        in_IN the_DT human_JJ host—hn_NN RNPK—could_NNP be_VB isolated_VBN by_IN direct_JJ binding_VBG to_TO a_DT viral_JJ fragment_NN derived_VBN
        from_IN the_DT HBV_NNP variant_NN of_IN these_DT infected_JJ patients_NNS ._.
        hnRNPK_NN has_VBZ previously_RB been_VBN shown_VBN to_TO be_VB involved_VBN in_IN several_JJ cellular_JJ functions—for_NN
        example_NN ,_, as_IN a_DT regulator_NN of_IN signal_NN transduction_NN and_CC of_IN gene_NN expression_NN ._. On_IN further_JJ
        examination_NN of_IN the_DT role_NN of_IN hnRNPK_NN in_IN HBV_NNP replication_NN ,_, they_PRP established_VBD that_DT hnRNPK_NN is_VBZ
        capable_JJ of_IN acting_VBG on_IN the_DT full_JJ length_NN of_IN HBV_NNP ,_, rather_RB than_IN just_RB a_DT partial_JJ fragment_NN ._. They_PRP
        compared_VBD four_CD full-length_JJ replicative_JJ HBV_NNP clones_NNS ,_, identical_JJ except_IN for_IN a_DT single_JJ base_NN change_NN
        at_IN position_NN 1752_CD ,_, that_WDT were_VBD transfected_JJ with_IN two_CD different_JJ hnRNPK_NN expression_NN constructs_NNS and_CC
        showed_VBD that_IN 1752_CD A_DT was_VBD more_RBR efficient_JJ at_IN promoting_VBG replication_NN than_IN the_DT other_JJ three_CD
        variants_NNS ._.
        To_TO further_VB show_NN the_DT role_NN of_IN hnRNPK_NN in_IN HBV_NNP replication_NN ,_, the_DT team_NN tested_VBD the_DT effect_NN of_IN
        over-expression_JJ and_CC down-regulation_JJ of_IN the_DT cellular_JJ protein_NN ._. Using_VBG siRNA_NN ,_, designed_VBN to_TO
        reduce_VB endogenous_JJ hnRNPK_NN ,_, they_PRP showed_VBD suppression_NN of_IN both_DT hnRNPK_NN mRNA_NN and_CC HBV_NNP viral_JJ load_NN ,_,
        whereas_IN a_DT control_NN siRNA_NN had_VBD no_DT effect_NN on_IN HBV_NNP viral_JJ load_NN ._.
        Despite_IN these_DT findings_NNS ,_, the_DT mechanism_NN behind_IN hnRNPK_NN on_IN HBV_NNP replication_NN needs_VBZ further_JJ
        exploration_NN ,_, the_DT authors_NNS say_VBP ,_, concluding_VBG that_IN viral_JJ replication_NN efficiency_NN was_VBD determined_VBN
        by_IN a_DT combination_NN of_IN viral_JJ sequence_NN and_CC interaction_NN with_IN specific_JJ host_NN proteins_NNS ._. However_RB ,_,
        they_PRP suggest_VBP that_IN these_DT results_NNS indicate_VBP that_IN although_IN drug_NN development_NN of_IN antivirals_NNS is_VBZ an_DT
        established_VBN research_NN avenue_NN ,_, targeting_VBG the_DT host_NN is_VBZ an_DT untapped_JJ opportunity_NN ._.
        They_PRP describe_VBP parallels_NNS with_IN anti-_NN EGFR_NNP antibody_NN treatment_NN of_IN breast_NN cancer_NN cells_NNS ,_, which_WDT
        produced_VBD a_DT decrease_NN in_IN cell_NN replication_NN rate_NN and_CC corresponding_JJ reduction_NN in_IN hnRNPK_NN
        expression_NN levels_NNS ;_: this_DT result_NN suggested_VBD that_IN hnRNPK_NN levels_NNS could_MD be_VB modulated_JJ by_IN anti-_NN EGFR_NNP
        treatment_NN ,_, thus_RB highlighting_VBG new_JJ treatment_NN options_NNS for_IN altering_VBG the_DT HBV_NNP viral_JJ load_NN in_IN
        chronic_JJ carriers_NNS ._.
        The_DT authors_NNS conclude_VBP that_IN the_DT future_NN of_IN long-term_JJ viral_JJ clearance_NN will_MD require_VB
        combination_NN therapy_NN of_IN targeting_VBG the_DT virus_NN directly_RB ,_, blocking_VBG host_NN support_NN proteins_NNS ,_, and_CC
        using_VBG immuno-modulating_JJ agents_NNS ._.
      
    
  
